TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26316226

Group type: EXPERIMENTAL
Intervention: Active lesions during at-risk (AR) period
Number of subjects: 69

Group type: COMPARATOR
Intervention: Active lesions during not-at-risk (not-AR) period
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Correlation of lesions with AR proportion
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Correlation of lesions with time from URI onset
Number of subjects: 69
Study: 23559265

Group type: EXPERIMENTAL
Intervention: New chronic poststroke pain (10.6% of participants, 1665 participants)
Number of subjects: 15754

Group type: EXPERIMENTAL
Intervention: Central poststroke pain (2.7%, 431 participants)
Number of subjects: 15754

Group type: EXPERIMENTAL
Intervention: Peripheral neuropathic pain (1.5%, 238 participants)
Number of subjects: 15754

Group type: EXPERIMENTAL
Intervention: Pain from spasticity (1.3%, 208 participants)
Number of subjects: 15754

Group type: EXPERIMENTAL
Intervention: Pain from shoulder subluxation (0.9%, 136 participants)
Number of subjects: 15754

Group type: EXPERIMENTAL
Intervention: More than 1 pain subtype (0.6%, 86 participants)
Number of subjects: 15754
Study: 21791660

Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H5N1 vaccine administered on different schedules (21 days, 14 days, 7 days apart, or same day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H5N1 vaccine administered on standard schedule (21 days apart)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H5N1 vaccine administered on accelerated schedules (14 days, 7 days apart, or same day)
Number of subjects: 0
Study: 19835535

Group type: EXPERIMENTAL
Intervention: Personalised weight measurement card and advice on optimal gestational weight gain; instructed to record weight at 16, 20, 24, 28, 30, 32 and 34 weeks' gestation
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group weighed at recruitment, no instructions about regular weight measurement
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Personalised weight measurement card and advice on optimal gestational weight gain; instructed to record weight at 16, 20, 24, 28, 30, 32 and 34 weeks' gestation (overweight but not obese)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group weighed at recruitment, no instructions about regular weight measurement (overweight but not obese)
Number of subjects: 236
Study: 17108585

Group type: EXPERIMENTAL
Intervention: Computer Reminder System (CRS) for antibiotics and asthma/COPD prescriptions
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Computer Reminder System (CRS) for cholesterol prescriptions
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: User-friendliness of the Computer Reminder System
Number of subjects: 53
Study: 15039413

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Medical care as usual
Number of subjects: 102
Study: 11369151

Group type: EXPERIMENTAL
Intervention: Verbal information with negative framing
Number of subjects: 300

Group type: COMPARATOR
Intervention: Verbal information with positive framing
Number of subjects: 300

Group type: COMPARATOR
Intervention: Numerical information
Number of subjects: 300
Study: 9720639

Group type: EXPERIMENTAL
Intervention: Tele-marketing
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Training and no support
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Training and minimal support
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Training and maximal support
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 161
Study: 7917777

Group type: EXPERIMENTAL
Intervention: Carbamazepine therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Drug-free controls
Number of subjects: 40
Study: 3073525

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 22
Study: 29753234

Group type: EXPERIMENTAL
Intervention: HZN+S (hazelnuts with skin)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HZN-S (hazelnuts without skin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (dietary recommendations only)
Number of subjects: 60
Study: 27344436

Group type: EXPERIMENTAL
Intervention: Protein C zymogen
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 26276278

Group type: EXPERIMENTAL
Intervention: Shortened systematic review format
Number of subjects: 56

Group type: COMPARATOR
Intervention: Full-length systematic review format
Number of subjects: 56
Study: 23690355

Group type: EXPERIMENTAL
Intervention: Retention Group with Transpalatal Arch (TPA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No Retention Group
Number of subjects: 30
Study: 20048655

Group type: EXPERIMENTAL
Intervention: Continuous interscalene ropivacaine infusion (ropivacaine 0.2% 2 mL/hr with patient‐controlled 5‐mL boluses every hour)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Continuous interscalene ropivacaine infusion
Number of subjects: 61

Group type: COMPARATOR
Intervention: Single-shot interscalene block (SS)
Number of subjects: 61
Study: 18701824

Group type: EXPERIMENTAL
Intervention: Different treatment strategies
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: CD14 genotype and concentrations of CRP and neopterin
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: CD14-260 TT genotype
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: CD14-260 TT genotype for children with 4 or more carious lesions
Number of subjects: 348
Study: 16772285

Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH) with pronase 5 IU/ml for 1 min at 37 degrees C
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (untreated embryos)
Number of subjects: 125
Study: 12361449

Group type: EXPERIMENTAL
Intervention: Combination of education and mattress encasement to reduce mite allergen exposure
Number of subjects: 636

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 636
Study: 9681396

Group type: EXPERIMENTAL
Intervention: Serum TNF-alpha levels in advanced cancer patients
Number of subjects: 27

Group type: COMPARATOR
Intervention: Serum TNF-alpha levels in healthy controls
Number of subjects: 27
Study: 8002642

Group type: EXPERIMENTAL
Intervention: 0.1% tretinoin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 28
Study: 2600262

Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish
Number of subjects: 10

Group type: COMPARATOR
Intervention: 10% chlorhexidine varnish
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (0% chlorhexidine varnish)
Number of subjects: 10
Study: 1096217

Group type: EXPERIMENTAL
Intervention: Cyproheptadine 4 mg three times daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31234530

Group type: EXPERIMENTAL
Intervention: Nut consumers
Number of subjects: 12946

Group type: COMPARATOR
Intervention: Non-nut consumers
Number of subjects: 12946
Study: 28264793

Group type: EXPERIMENTAL
Intervention: Online group-based self-tracking
Number of subjects: 111

Group type: COMPARATOR
Intervention: Individual self-tracking (control group)
Number of subjects: 111
Study: 23968654

Group type: EXPERIMENTAL
Intervention: Single-bolus propofol (2 mg/kg) based on corrected body weight (CBW60)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Single-bolus propofol (2 mg/kg) based on total body weight (TBW)
Number of subjects: 38
Study: 21894361

Group type: EXPERIMENTAL
Intervention: Quality of life improvement plan
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 123
Study: 20034314

Group type: EXPERIMENTAL
Intervention: Standing passengers who held hand straps
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Passengers sitting on the centre of the rear seat
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Passengers facing the window and standing transversely
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: First sudden stop
Number of subjects: 16
Study: 17764003

Group type: EXPERIMENTAL
Intervention: Intra-articular bupivacaine (20 ml of 0.25%)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (20 ml of 0.9% NaCl)
Number of subjects: 26
Study: 14730317

Group type: EXPERIMENTAL
Intervention: GM soya
Number of subjects: 7
Study: 11164126

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) > or = 150 mm Hg
Number of subjects: 17762

Group type: COMPARATOR
Intervention: Systolic Blood Pressure (SBP) < 120 mm Hg
Number of subjects: 17762

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) > or = 90 mm Hg
Number of subjects: 17762

Group type: COMPARATOR
Intervention: Diastolic Blood Pressure (DBP) < 70 mm Hg
Number of subjects: 17762

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 17762

Group type: EXPERIMENTAL
Intervention: Antihypertensive medications
Number of subjects: 17762
Study: 9735663

Group type: EXPERIMENTAL
Intervention: HBeAg-positive sera
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HBeAg-negative sera
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anti-TP antibodies
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anti-RT antibodies
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anti-RNase H antibodies
Number of subjects: 40
Study: 8285197

Group type: EXPERIMENTAL
Intervention: High-efficiency cuprammonium rayon dialyzer
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-efficiency polysulfone dialyzer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amount of dialysis (Kt/V urea)
Number of subjects: 0
Study: 2365214

Group type: EXPERIMENTAL
Intervention: SF-ELS
Number of subjects: 157

Group type: COMPARATOR
Intervention: PEG-ELS
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 157
Study: 1089426

Group type: EXPERIMENTAL
Intervention: QX-572, 8 mg/kg body weight, administered as a slow intravenous infusion over 30 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group receiving saline, administered as a slow intravenous infusion over 30 minutes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: QX-572
Number of subjects: 10
Study: 30764635

Group type: EXPERIMENTAL
Intervention: Interferential current treatment for 30 minutes, twice a day for five days postoperatively.
Number of subjects: 113

Group type: COMPARATOR
Intervention: Sham interferential current treatment (same pads applied without electrical stimulation).
Number of subjects: 113
Study: 28539196

Group type: EXPERIMENTAL
Intervention: Informed Health Choices podcast
Number of subjects: 675

Group type: COMPARATOR
Intervention: Public service announcements (control group)
Number of subjects: 675
Study: 26077006

Group type: EXPERIMENTAL
Intervention: Rheohaemapheresis treatment
Number of subjects: 23
Study: 24300626

Group type: EXPERIMENTAL
Intervention: Aspen Ceftriaxone (AC)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Rocephin (ROC)
Number of subjects: 63
Study: 21694649

Group type: EXPERIMENTAL
Intervention: Nicergoline (15 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Imidapril (5 mg/d)
Number of subjects: 60
Study: 19307792

Group type: EXPERIMENTAL
Intervention: Early corticosteroid withdrawal
Number of subjects: 37

Group type: COMPARATOR
Intervention: Chronic steroids (Control)
Number of subjects: 37
Study: 16696632

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum plus health education (HE)
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum plus motivational interviewing (MI)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Placebo gum plus health education (HE)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Placebo gum plus motivational interviewing (MI)
Number of subjects: 755
Study: 16642605

Group type: EXPERIMENTAL
Intervention: Head point-through-point electroacupuncture and oral administration of madopa
Number of subjects: 76

Group type: COMPARATOR
Intervention: Oral administration of madopa
Number of subjects: 76
Study: 12841373

Group type: EXPERIMENTAL
Intervention: Sleep bruxism patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 10063814

Group type: EXPERIMENTAL
Intervention: Precooling (PC)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 6
Study: 7554974

Group type: EXPERIMENTAL
Intervention: 400 micrograms misoprostol orally
Number of subjects: 64

Group type: COMPARATOR
Intervention: 1 mg vaginal gemeprost
Number of subjects: 64
Study: 2182615

Group type: EXPERIMENTAL
Intervention: L-tryptophan
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Artificial evening light
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: L-tryptophan and artificial evening light
Number of subjects: 13
Study: 84706

Group type: EXPERIMENTAL
Intervention: CHOP regimens (cyclophosphamide, adriamycin, vincristine, and prednisone with either low-dose bleomycin or BCG by scarification)
Number of subjects: 443

Group type: COMPARATOR
Intervention: COP regimen (cyclophosphamide, vincristine, and prednisone with low-dose bleomycin)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: CHOP regimens
Number of subjects: 443

Group type: COMPARATOR
Intervention: COP regimen
Number of subjects: 443
Study: 31515152

Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy (HFOT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 20
Study: 28722093

Group type: EXPERIMENTAL
Intervention: Wheat cellulose particles (1 bag, 2 times per day) + Diosmin tablet (2 pills, 2 times per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diosmin tablet (2 pills, 2 times per day)
Number of subjects: 60
Study: 25422075

Group type: EXPERIMENTAL
Intervention: E-learning education programme
Number of subjects: 0
Study: 23798635

Group type: EXPERIMENTAL
Intervention: Aggressive parenteral nutrition (APN)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard parenteral nutrition (SPN)
Number of subjects: 34
Study: 21563508

Group type: EXPERIMENTAL
Intervention: biomedical therapy (diclofenec, methotrexate, and sulfasalazine)
Number of subjects: 194
Study: 19318436

Group type: EXPERIMENTAL
Intervention: Expert Sources (ES)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Unattributed Risk Information (URI)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control Condition (CC)
Number of subjects: 284
Study: 17121380

Group type: EXPERIMENTAL
Intervention: Inosine (1-2 g daily, given twice)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no treatment except for relapse period)
Number of subjects: 32
Study: 15253256

Group type: EXPERIMENTAL
Intervention: Pre-cuffed PTFE graft
Number of subjects: 89

Group type: COMPARATOR
Intervention: PTFE graft with vein cuff
Number of subjects: 89
Study: 10899382

Group type: EXPERIMENTAL
Intervention: Mecamylamine 5 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mecamylamine 10 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mecamylamine 20 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 9273914

Group type: EXPERIMENTAL
Intervention: Sober behavioral standard (FB reinforcement)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intoxicated behavioral standard (FB reinforcement)
Number of subjects: 12
Study: 8360128

Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment
Number of subjects: 99

Group type: COMPARATOR
Intervention: Chlorhexidine/neomycin (Naseptin) cream
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment following failure with chlorhexidine/neomycin
Number of subjects: 99
Study: 3019375

Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazapril 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazapril 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazapril (all doses)
Number of subjects: 12
Study: 31789531

Group type: EXPERIMENTAL
Intervention: PRISMS (n = 92)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control (existing resource with psychoeducation about sexual orientation, n = 92)
Number of subjects: 184
Study: 31822285

Group type: EXPERIMENTAL
Intervention: Fried Phenotype (FP)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Comprehensive Frailty Assessment Instrument (CFAI)
Number of subjects: 196
Study: 28667228

Group type: EXPERIMENTAL
Intervention: PATHway (internet‐enabled, sensor‐based home CR platform with individualised heart rate monitored exercise programmes)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PATHway
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 26230741

Group type: EXPERIMENTAL
Intervention: Gabapentin 1300 mg/d
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/d
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Gabapentin 1300 mg/d and 900 mg/d
Number of subjects: 300
Study: 24051993

Group type: EXPERIMENTAL
Intervention: Virtual reality training using Xbox Kinect and conventional occupational therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional occupational therapy alone
Number of subjects: 40
Study: 22132634

Group type: EXPERIMENTAL
Intervention: MiniArc
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: AJUST
Number of subjects: 66
Study: 19219405

Group type: EXPERIMENTAL
Intervention: SC low-molecular-weight heparin (LMWH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: SC unfractionated heparin (UFH)
Number of subjects: 24
Study: 16990410

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate for 24 months in addition to antihypertensive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15548851

Group type: EXPERIMENTAL
Intervention: Lansoprazole fast disintegrating tablet (LFDT) with 150 mL of water
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lansoprazole fast disintegrating tablet (LFDT) without water (with saliva)
Number of subjects: 12
Study: 11772907

Group type: EXPERIMENTAL
Intervention: Metformin (up to 1,000 mg twice daily)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 82
Study: 9599500

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 67

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 67
Study: 7506223

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon-alpha 2a, administered in tapering doses thrice weekly for 1 year
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon-alpha 2a
Number of subjects: 60
Study: 2525870

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 31039001

Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly crosslinked polyethylene (HXLPE) insert
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional polyethylene insert
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Vitamin E-infused HXLPE insert
Number of subjects: 200
Study: 28605291

Group type: COMPARATOR
Intervention: Carboplatin and Etoposide (CE)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Carboplatin, Etoposide, and Palifosfamide (PaCE)
Number of subjects: 188
Study: 25136139

Group type: EXPERIMENTAL
Intervention: Patient narratives (1-hour long) followed by discussion
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control teaching (conventional faculty-delivered teaching)
Number of subjects: 283
Study: 23039321

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg bid
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study: 21819707

Group type: EXPERIMENTAL
Intervention: New peritoneal trocar
Number of subjects: 376

Group type: COMPARATOR
Intervention: Conventional laparotomy
Number of subjects: 376
Study: 19567647

Group type: EXPERIMENTAL
Intervention: Combined radiofrequency ablation and TACE
Number of subjects: 89

Group type: COMPARATOR
Intervention: Radiofrequency ablation alone
Number of subjects: 89
Study: 16539287

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid pack (Merogel)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No packing (Control)
Number of subjects: 42
Study: 15499518

Group type: EXPERIMENTAL
Intervention: Carl Zeiss IOL-Master 99 (IOLM)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Biovision Echograph Class 1 - Type B (BIOV)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Allergan Humphrey Ultrasonic Biometer Mod. 820 (AHUB)
Number of subjects: 59
Study: 10880059

Group type: EXPERIMENTAL
Intervention: Psychosocial factors (intrapersonal, stress-processing, social ecological)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Biomedical factors
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Psychosocial factors
Number of subjects: 90
Study: 8777472

Group type: COMPARATOR
Intervention: Carvedilol (C)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Enalapril (E)
Number of subjects: 248
Study: 1585843

Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Friendly social cues
Number of subjects: 88

Group type: COMPARATOR
Intervention: Unfriendly social cues
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Alcohol content
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Amount of beverage consumed
Number of subjects: 88
Study: 24049904

Group type: EXPERIMENTAL
Intervention: Energy supplement with 200 mg of monensin added/kg of feed
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Protein supplement with 200 mg of monensin added/kg of feed
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (energy supplement)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (protein supplement)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Monensin-treated cows (experiment I)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Monensin-treated cows (experiment II)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Monensin supplementation
Number of subjects: 38